209results about "Pancreatic cells" patented technology

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some embodiments, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some embodiments, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

The present disclosure provides methods of making tissue-derived epithelial organoids. In particular, the present disclosure provides a tissue-derived epithelial organoid embedded in a hydrogel suspended in a culture medium. The present disclosure further provides methods of using such organoids.

The invention relates to the field of cell biology, and particularly relates to a preparation method of a pancreatic cancer-related antigen-loaded polypeptide, which is characterized in that factors such as GM-CSF, IL-4, IFN-gamma, TNF-alpha, IL-1beta, IL-6, PGE2, Poly I: C, R848 and the like are added to promote mononuclear cells to be activated into DC cells, pancreatic cancer PANC-1, MIA PaCa-2, BxPC-3, KP4 and SW1990HM antigens are loaded, and not only is DC cell maturation promoted, but also pancreatic cancer-related antigens are loaded. The positive rate of CD83 + CD86 of the DC cells cultured by the method is 94.16%, and the secretion amount of IL-12p70 in a cell supernatant is (645.38 + / -36.49) pg / mL. By adopting the culture method disclosed by the invention, the maturation rate of the DC cells can be improved while the DC cells are activated, so that the culture method for promoting the maturation and amplification of the DC cells loaded with the pancreatic cancer antigen is achieved.

Disclosed herein are intravascular artificial pancreas devices and methods for their manufacture.

Embodiments herein describe tools, instruments and methods for aseptic loading, dispensing and / or delivering cells into an implantable device and aseptically and selectively scaling a device inside a sterile package as well as and storing and preparing for shipment the cell-filled device.

The present disclosure relates to a transplantable cell therapy product composition for diabetes mellitus that contains an aggregate of insulin-secreting cells derived from stem cells. In the present disclosure, an NF microwell array membrane was fabricated by applying a molding process to an electrospun, permeable, biodegradable polycaprolactone (PCL) NF membrane and thus allows gases and soluble factors to permeate therethrough. The NF microwell of the present disclosure could provide more nutrients to the iPSC aggregates than conventional impermeable PDMS microwells, thus enhancing survival and differentiation capabilities of the cells. Additionally, the NF membrane was attached singly to the subcutaneous tissue and to the surface of organs such as liver and peritoneum without the need for a fixing material or separate sutures and was integrated with surrounding tissues, resulting in higher insulin secretion than PDMS microwells. Therefore, the present disclosure can be effectively utilized as a composition for the prevention or treatment of diabetes.

Disclosed herein include methods, compositions, and kits suitable for use in cell therapy. In some embodiments, there are provided methods and compositions for differentiating stem cells into pancreatic beta cells capable of producing insulin.

The present disclosure provides methods of amplifying tissue samples derived from humans for purposes of treating certain diseases. The method comprises: isolating a small amount of associated tissue by biopsy or other tissue acquisition methods; the tissue is amplified in vitro, and meanwhile, natural functions are reserved; and re-implanting the amplified tissue to alleviate human disease. One example includes ex vivo expansion of human pancreatic islet tissue and reimplantation of the expanded cells into an individual with Type 1 diabetes for treatment and long term relief or cure of disease.

The invention provides for methods of differentiating pancreatic endocrine cells into pancreatic beta cells expressing PDX1, NKX6.1, MAFA, UCN3 and SLC2A. These pancreatic beta cells may be obtained by step-wise differentiation of pluripotent stem cells. The pancreatic beta cells exhibit glucose-dependent mitochondrial respiration and glucose-stimulated insulin secretion similar to islet cells.

The application provides an islet-vascular co-culture system based on a microfluidic chip, a building method and application, and the building method of the islet-vascular co-culture system comprises the following steps: S1, preparing microfibers loaded with islets; S2, preparing an assembled chip, the assembled chip comprises a containing cavity, first microchannel networks and second microchannel networks are symmetrically arranged on two sides of the containing cavity, and the first microchannel networks and the second microchannel networks are respectively communicated with a liquid inlet and a liquid outlet at an end away from the containing cavity; S3, controlling the flow of the liquid inlet to be 6-8 muL / min to carry out dynamic culture. The application can simulate the key structure and characteristics of islet tissue, can evaluate a diabetes treatment drug in vitro, can bridge the gap between in vitro and in vivo models, and can provide new tools and methods for the fields of drug development, disease model construction and personalized medical treatment.

The present disclosure relates to an in vitro method for enhancing engraftment of isolated pancreatic cells comprising the step of contacting an isolated pancreatic cell prior to a transplantation in a subject in need thereof, with a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate of the compound of general formula I:

The present invention provides a method for lowering blood glucose levels in an animal by transplanting a population of pancreatic endocrine precursor cells into an animal.

A novel method of inducing or producing hepatocytes from human induced pluripotent stem cells at an unprecedented efficiency and functionality. The core of the invention is the use of experimentally discovered mRNAs at multiple critical differentiation decision points along a pluripotent to mesendoderm to endoderm to hepatocytes pathway in a previously unknown manner.

An object of the present invention is to provide a novel method for inducing the differentiation of pluripotent stem cells into an insulin-positive cell population. The present invention provides a method for producing an insulin-positive cell population, comprising culturing and differentiating a pancreatic progenitor cell population or a cell population at a later stage of differentiation in a medium containing substantially no 2-(3-(6-methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine and containing a factor having ALK5-inhibiting activity and CDK8 / 19-inhibiting activity.

To overcome certain shortcomings of current embryonic stem cells and iPS cells, we provide novel stem cells for treating various diseases or conditions. [Solution] Lethal pluripotent stem cells produced in vitro from extraembryonic stem cells such as trophoblast stem cells, compositions thereof, and their use are disclosed herein. A method for producing a cell population by culturing lethal pluripotent stem cells produced in vitro with one or more inducers is also disclosed herein. A method for treating a disorder or condition by utilizing the cells disclosed herein and cells differentiated therefrom is also disclosed herein.

Provided herein are systems of modulating gene expression, methods of use thereof, and cells engineered thereof for the purpose of differentiating cells, for example beta cells.

Disclosed herein is the lethal pluripotent stem cell produced in vitro from extraembryonic stem cells such as trophoblast stem cells, its composition and its use.Disclosed herein is also the method of culturing the lethal pluripotent stem cell produced in vitro with one or more inducers to produce cell population.Disclosed herein is also the method of treating disorders or conditions by using the cells disclosed herein and the cells differentiated therefrom.

The present invention provides a new site for transplantation. Specifically, the present invention relates to a method for transplanting cells or tissues, particularly pancreatic islets, into the sub-rectus sheath site. The present invention also relates to a method for treating diabetes by transplanting pancreatic islets, particularly hPSC pancreatic islets, into a sub-rectus sheath position.

Provided herein, inter alia, are methods and compositions for treating diabetes mellitus comprising co-transplantation of an insulin-producing cell and a cell derived from a parathyroid gland (PTG), a CD34+ cell derived from a parathyroid gland, a CD34+ cell derived from a stem cell, or other progenitor cell-derived CD34+ cell.

Macroencapsulation devices and their methods of use are disclosed. In one embodiment, a macroencapsulation device may include a first outer membrane, a second outer membrane, and at least one semipermeable membrane disposed there between to form at least a primary compartment configured to house a first population of cells and a secondary compartment in fluid communication with the primary compartment through the first semipermeable membrane. In some embodiments, the flow of material into and out of the compartments of the macroencapsulation device and / or the application of an appropriate pressure differential between the compartments may be used to control the flow of filtrates, ancillary agents, and other materials between the compartments of the device when positioned in vivo.

The invention relates to a method of differentiating pancreatic bi-potent progenitor cells into beta cells comprising cultivating pancreatic endocrine precursor cells in a medium that promotes the cAMP signalling pathway that lies downstream of apical-basal polarity in endocrine precursors, which can be used to increase the differentiation of progenitor cells into beta cells. Furthermore, the present invention relates to a method of enriching and / or isolating one or more cells expressing a marker of apical-basal polarity, thereby isolating beta cells, and to a method of producing a population of beta cells from a population of human embryonic stem cells. Furthermore, the present invention relates to a population of beta cells obtainable by the method, a pharmaceutical composition comprising the beta cells, a cell culture of progenitor cells in a medium comprising a cAMP agonist, a complex comprising a beta cell bound by the binding agents specific for CD133 and CD49a, and a use of specific binding partners for isolating beta cells.

Provided herein are methods and systems for bio-printing of three-dimensional organs and organoids. Also provided herein are bio-printed / extruded three-dimensional lymphoid organoids for use in the generation and / or the assessment of immunological products and / or immune responses. Also provided herein are methods and system for lymphoid organoids for use in antigen and epitope discovery, characterizing immune response, and therapeutic compounds testing.

The present disclosure provides compositions, kits, and methods for promoting in vitro maturation of cells. The compositions, kits, and methods utilize at least one inhibitor of an epigenetic regulator and at least one agonist of a calcium channel. Suitable applications of the present disclosure include use in maturing and differentiation stem cells into viable mature neuronal cells for use in disease modeling, prevention and treatment. The present disclosure also provides methods of screening compounds that are suitable for promoting in vitro maturation of cells.

The present application discloses cell clusters resembling the function and characteristics of endogenous pancreatic islets, and methods for making and using such cell clusters.

The invention relates to the technical field of biological medicines, in particular to a preparation containing mesenchymal stem cell-derived insulin-secreting cells and application of the preparation in preparation of blood sugar regulating products. The insulin-secreting cell is derived from mesenchymal stem cells, and the preparation method of the insulin-secreting cell adopts a four-stage directional induced differentiation strategy: in the first stage, all-trans retinoic acid, LDN-193189 and cyclopamine are combined, an endoderm program is started, non-target differentiation is specifically inhibited, and pedigree locking is realized; in the second stage and the third stage, a high-glucose environment and GLP-1 are utilized to promote the cells to differentiate into endocrine precursors and terminal insulin secreting cells; in the fourth stage, GLP-1, PTHrP and nicotinic acid are added for function strengthening, and the glucose responsiveness, maturity and stress resistance of the cells are synergistically improved. The method is accurate in differentiation path and economic in factor, and the obtained cells are high in insulin positive rate and mature in function. A preparation containing the cell can be used for preparing a medicine for treating diabetes mellitus.

The present invention relates to a composition for inducing differentiation of human induced pluripotent stem cells into insulin-producing cells, and a method for inducing differentiation into insulin-producing cells by using the composition.

The purpose of the present invention is to provide a novel method for inducing differentiation of an insulin-positive cell population from pluripotent stem cells. Provided is a method for producing an insulin-positive cell population, the method including differentiating a pancreatic progenitor cell population, or a cell population thereof at a later stage of differentiation, in medium containing a CDK8 / 19 inhibitor.

To provide a method that sustains proliferation of mature pancreatic islet cells by a Mycl gene and enables continuous induction of proliferation.SOLUTION: The present invention provides a method for promoting and / or sustaining, by a glucose stimulation activation pathway activator, the proliferation activity of pancreatic islet cells in which a Mycl gene or a gene product thereof has been introduced or expressed through induction. More specifically, in the method, the Mycl gene includes (1) a nucleic acid having a base sequence represented by SEQ ID NO: 1 or 3, or (2) a nucleic acid that hybridizes with, under stringent conditions, a nucleic acid having a base sequence represented by SEQ ID NO: 1 or 3, and that encodes a polypeptide having a function of sustaining and / or promoting the proliferation activity of pancreatic islet-like cells when expression of the Mycl gene is induced.SELECTED DRAWING: None

This specification provides a method for administering engineered island cells containing functionally modified beta cells that include one or more modifications (such as genetic modifications). In some embodiments, the engineered island cells are low immunogenic cells. In some embodiments, the one or more modifications reduce or eliminate the expression of one or more MHC class I and / or MHC class II human leukocyte antigens and further increase the expression of one or more tolerance factors (such as CD47). In some embodiments, the subjects have a beta cell-related disorder such as diabetes (e.g., type 1 diabetes).